Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Moderna shares plunge on plans to cut $1.1 billion in costs, launch 10 new products by 2027
Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.
Moderna lays out plan to slice research and development spending
Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even.
Moderna stock plunges nearly 20% as company reports poor COVID-19 vaccine sales and cuts to research plans
Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over the next three years, a result of low sales projections and poor vaccine sales.
Moderna touts research progress as it cuts R&D spending by $1.1 billion
After being criticized for profligate post-pandemic spending, the company is "pacing" itself to focus on launches of key medicines.
Moderna Stock Drops on Plans To Cut $1.1B in R&D Costs
Moderna shares fell Thursday morning as the COVID vaccine maker said it plans to cut R&D spending by $1.1 billion over the next three years.
Moderna to Cut Research, Development Spending, Prioritize New Product Approvals
Moderna (MRNA) said Thursday it plans to cut back on its research and development spending as the company looks to save costs and prioritize the launch of new products already in the pipeline. The drugmaker expects to reduce its annual R&D budget to a range between $3.
Investor's Business Daily on MSN
6d
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.
7d
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
8d
on MSN
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...
3d
Behind the Scenes of Moderna's Latest Options Trends
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of ...
6d
Moderna’s ‘Off-the-Shelf’ Cancer Vaccine Shows Promise in Early Human Trial Data
The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...
4d
COVID-19 2024 fall guide: Everything Canadians should know about new Moderna vaccine, current variants and more
NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...
10d
Moderna forecasts lower sales next year, shares near four-year low
Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...
9d
on MSN
Moderna Stock Keeps Falling. An Analyst's Downgrade Isn't Helping
Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.
2d
Down 13% in 1 Day, Is Moderna Stock in Trouble?
Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Jim Cramer
MRNA
Spikevax
COVID-19
Period
Feedback